CoChat

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

Open access
Moyo-Gwete, Thandeka, Madzivhandila, Mashudu, Makhado, Zanele, Ayres, Frances, Mhlanga, Donald, Oosthuysen, Brent, Lambson, Bronwen E., Kgagudi, Prudence, Tegally, Houriiyah, Iranzadeh, Arash, Doolabh, Deelan, Tyers, Lynn, Chinhoyi, Lionel R., Mennen, Mathilda, Skelem, Sango, Marais, Gert, Wibmer, Constantinos Kurt, Bhiman, Jinal N, Ueckermann, Veronica, Rossouw, Theresa, Boswell, Michael, de Oliveira, Tulio, Williamson, Carolyn, Burgers, Wendy A, Ntusi, Ntobeko, Morris, Lynn, Moore, Penny L · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
PreprintCited by 36

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - when over 90% of infections in South Africa were attributed to 501Y.V2. Robust binding and neutralizing antibody titers to the 501Y.V2 variant were detected and these binding antibodies showed high levels of cross-reactivity for the original variant, from the first wave. In contrast to an earlier study where sera from individuals infected with the original variant showed dramatically reduced potency against 501Y.V2, sera from 501Y.V2-infected patients maintained good cross-reactivity against viruses from the first wave. Furthermore, sera from 501Y.V2-infected patients also neutralized the 501Y.V3 (P.1) variant first described in Brazil, and now circulating globally. Collectively these data suggest that the antibody response in patients infected with 501Y.V2 has a broad specificity and that vaccines designed with the 501Y.V2 sequence may elicit more cross-reactive responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.03.06.434193

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 29

  1. 2020, Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomes, Bioinformatics, 36, 3552, 10.1093/bioinformatics/btaa145 · DOI · Paper page
  2. 2020, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial, The Lancet, 396, 467, 10.1016/S0140-6736(20)31604-4 · DOI · Paper page
  3. Fontanet, A. , Autran, B. , Lina, B. , Kieny, M. P. , Karim, S. S. A. & Sridhar, D. 2021. SARS-CoV-2 variants and ending the COVID-19 pandemic. The Lancet. · DOI · Paper page
  4. Garcia-Beltran, W. F. , Lam, E. C. , Denis, K. S. , Nitido, A. D. , Garcia, Z. H. , Hauser, B. M. , Feldman, J. , Pavlovic, M. N. , Gregory, D. J. & Poznansky, M. C. 2021. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv. · DOI · Paper page
  5. Gavor, E. , Choong, Y. K. , Er, S. Y. , Sivaraman, H. & Sivaraman, J. 2020. Structural basis of SARS-CoV-2 and SARS-CoV–antibody interactions. Trends in Immunology. · DOI
  6. Huang, Y. , Nguyen, A. W. , Hsieh, C.-L. , Silva, R. , Olaluwoye, O. S. , Wilen, R. , Kaoud, T. S. , Azouz, L. R. , Qerqez, A. N. & Le, K. C. 2021. Identification of a conserved neutralizing epitope present on spike proteins from highly pathogenic coronaviruses. bioRxiv. · DOI
  7. 10.1093/molbev/mst010 · DOI · Paper page
  8. Korber, B. , Fischer, W. , Gnanakaran, S. , Yoon, H. , Theiler, J. , Abfalterer, W. , Foley, B. , Giorgi, E. , Bhattacharya, T. , Parker, M. , Partridge, D. , Evans, C. , De Silva, T. , Labranche, C. & Montefiori, D. 2020a. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv, 2020.04.29.069054.
  9. 10.1016/j.cell.2020.06.043 · DOI · Paper page
  10. 2020, Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity, Immunity, 53, 1272, 10.1016/j.immuni.2020.10.023 · DOI · Paper page
  11. Liu, H. , Zhang, Q. , Wei, P. , Chen, Z. , Aviszus, K. , Yang, J. , Downing, W. , Peterson, S. , Jiang, C. , Liang, B. , Reynoso, L. , Downey, G. P. , Frankel, S. K. , Kappler, J. , Marrack, P. & Zhang, G. 2021. The basis of a more contagious 501Y.V1 variant of SARS-COV-2. bioRxiv, 2021.02.02.428884.
  12. Madhi, S. A. , Baillie, V. L. , Cutland, C. L. , Voysey, M. , Koen, A. L. , Fairlie, L. , Padayachee, S. D. , Dheda, K. , Barnabas, S. L. & Bhorat, Q. E. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B. 1.351 variant in South Africa. medRxiv. · DOI · Paper page
  13. 2020, Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques, Nature, 586, 583, 10.1038/s41586-020-2607-z · DOI · Paper page
  14. 10.1093/molbev/msu300 · DOI · Paper page
  15. 2020, Whole genome sequencing of SARS-CoV-2: adapting Illumina protocols for quick and accurate outbreak investigation during a pandemic, Genes, 11, 949, 10.3390/genes11080949 · DOI
  16. Rappazzo, C. G. , Longping, V. T. , Kaku, C. I. , Wrapp, D. , Sakharkar, M. , Huang, D. , Deveau, L. M. , Yockachonis, T. J. , Herbert, A. S. & Battles, M. B. 2021. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. · DOI · Paper page
  17. Rawat, K. , Kumari, P. & Saha, L. 2020. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European journal of pharmacology, 173751.
  18. Stamatatos, L. , Czartoski, J. , Wan, Y.-H. , Homad, L. J. , Rubin, V. , Glantz, H. , Neradilek, M. , Seydoux, E. , Jennewein, M. F. , Maccamy, A. J. , Feng, J. , Mize, G. , De Rosa, S. C. , Finzi, A. , Lemos, M. , Cohen, K. W. , Moodie, Z. , Mcelrath, M. J. & Mcguire, A. T. 2021. Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1. medRxiv, 2021.02.05.21251182.
  19. Wang, L. , Zhou, T. , Zhang, Y. , Yang, E. S. , Schramm, C. A. , Shi, W. , Pegu, A. , Oloninyi, O. K. , Ransier, A. , Darko, S. , Narpala, S. R. , Hatcher, C. , Martinez, D. R. , Tsybovsky, Y. , Phung, E. , Abiona, O. M. , Cale, E. M. , Chang, L. A. , Corbett, K. S. , Dipiazza, A. T. , Gordon, I. J. , Leung, K. , Liu, T. , Mason, R. D. , Nazzari, A. , Novik, L. , Olia, A. S. , Doria-Rose, N. A. , Stephens, T. , Stringham, C. D. , Talana, C. A. , Teng, I.-T. , Wagner, D. , Widge, A. T. , Zhang, B. , Roederer, M. , Ledgerwood, J. E. , Ruckwardt, T. J. , Gaudinski, M. R. , Baric, R. S. , Graham, B. S. , Mcdermott, A. B. , Douek, D. C. , Kwong, P. D. , Mascola, J. R. , Sullivan, N. J. & Misasi, J. 2021a. Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants. bioRxiv, 2021.02.25.432969.
  20. Wang, P. , Nair, M. S. , Liu, L. , Iketani, S. , Luo, Y. , Guo, Y. , Wang, M. , Yu, J. , Zhang, B. , Kwong, P. D. , Graham, B. S. , Mascola, J. R. , Chang, J. Y. , Yin, M. T. , Sobieszczyk, M. , Kyratsous, C. A. , Shapiro, L. , Sheng, Z. , Huang, Y. & Ho, D. D. 2021b. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. bioRxiv, 2021.01.25.428137.
  21. Wang, P. , Wang, M. , Yu, J. , Cerutti, G. , Nair, M. S. , Huang, Y. , Kwong, P. D. , Shapiro, L. & HO, D. D. 2021 c. Increased Resistance Of SARS-CoV-2 Variant P.1 to Antibody Neutralization . bioRxiv, 2021.03.01.433466.
  22. Wibmer, C. K. , Ayres, F. , Hermanus, T. , Madzivhandila, M. , Kgagudi, P. , Oosthuysen, B. , Lambson, B. E. , De Oliveira, T. , Vermeulen, M. , Van Der Berg, K. , Rossouw, T. , Boswell, M. , Ueckermann, V. , Meiring, S. , Von Gottberg, A. , Cohen, C. , Morris, L. , Bhiman, J. N. & Moore, P. L. 2021. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine. · DOI · Paper page
  23. Wickham, H. 2016. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag: New York, NY, USA. · DOI · Paper page
  24. Wise, J. 2021. Covid-19: The E484K mutation and the risks it poses. British Medical Journal Publishing Group. · DOI · Paper page
  25. Wu, K. , Werner, A. P. , Moliva, J. I. , Koch, M. , Choi, A. , Stewart-Jones, G. B. E. , Bennett, H. , Boyoglu-Barnum, S. , Shi, W. , Graham, B. S. , Carfi, A. , Corbett, K. S. , Seder, R. A. & Edwards, D. K. 2021. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv, 2021.01.25.427948.
  26. 10.1126/science.abc6284 · DOI · Paper page
  27. Zhang, L. , Jackson, C. B. , Mou, H. , Ojha, A. , Rangarajan, E. S. , Izard, T. , Farzan, M. & Choe, H. 2020a. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv, 2020.06.12.148726.
  28. Zhang, Y.-J. , Zeng, G. , Pan, H.-X. , Li, C.-G. , Kan, B. , Hu, Y.-L. , Mao, H.-Y. , Xin, Q.-Q. , Chu, K. & Han, W.-X. 2020b. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. medrxiv. · DOI
  29. 10.1038/s41586-020-2012-7 · DOI · Paper page

Cited by

See all 36

Metadata

Authors
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., Doolabh, D., Tyers, L., Chinhoyi, L. R., Mennen, M., Skelem, S., Marais, G., Wibmer, C. K., Bhiman, J. N., Ueckermann, V., Rossouw, T., Boswell, M., de Oliveira, T., Williamson, C., Burgers, W. A., Ntusi, N., Morris, L., & Moore, P. L.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2021-03-06
OpenAlex
W3135007751
Cited by
36
References
13
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. https://app.cochat.ai/papers/10.1101/2021.03.06.434193
The paper
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., Doolabh, D., Tyers, L., Chinhoyi, L. R., Mennen, M., Skelem, S., Marais, G., Wibmer, C. K., Bhiman, J. N., Ueckermann, V., . . . Moore, P. L. (2021). SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2021.03.06.434193

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.